Data Sheet 5_Sustained complete response to TMEp-CI-M platform in refractory small-cell lu

A single-case report authored by Yating Wu details a 60-year-old male patient with PD-L1-negative extensive-stage small-cell lung cancer and brainstem metastasis. The patient was treated with the TMEp-CI-M platform, achieving no evidence of disease for over 20 months, with ProGRP levels dropping from 1803 pg/mL to 23.71 pg/mL. The report was uploaded to figshare on 2026-06-01 and is shared under a CC-BY-4.0 license.

Use Cases

• Analyze the clinical timeline and biomarker response (ProGRP levels) described in the case report
• Study the components and sequencing of the TMEp-CI-M therapeutic platform (SBRT, low-dose etoposide, anlotinib, cadonilimab, probiotics)
• Review a documented instance of long-term disease-free survival in a rare and aggressive cancer presentation (brainstem metastasis from SCLC)

Strengths

• Provides detailed longitudinal clinical data for a single patient over more than 20 months of follow-up
• Includes specific biomarker measurements (ProGRP levels before and after treatment) and adverse event reporting
• The full-text case report is available for review as a 910.3 KB PDF file

Limitations

• The dataset is a single-case report (n=1), limiting statistical generalizability
• Row count and column-level documentation are unknown; data is embedded in narrative text
• Data may reflect the specific clinical context of a single patient and institution

Provenance

Source

Yating Wu

Collection Method

Clinical case documentation and reporting

Time Range

Covers a patient treatment and follow-up period of over 20 months prior to the report's publication in 2026

Freshness

Last updated 2026-06-01 05:18:40